ARTICLE | Emerging Company Profile
OncoOne: targeting oxidized MIF for solid tumors
Led by Shire vets, the Austrian biotech is taking aim at a highly selective tumor antigen the biotech left behind
March 19, 2020 12:37 AM UTC
A trio of Shire veterans launched OncoOne on Wednesday with a €13 million series A round and a batch of biologics against oxidized MIF, a highly selective tumor antigen that was abandoned by the pharma when it shifted away from oncology R&D.
While the unmodified form of MIF, a well-known cytokine, is distributed throughout healthy tissues, the oxidized form is highly tumor cell-specific...
BCIQ Company Profiles
BCIQ Target Profiles